SG11201901435UA - Monoclonal antibody against melk and utilization thereof - Google Patents
Monoclonal antibody against melk and utilization thereofInfo
- Publication number
- SG11201901435UA SG11201901435UA SG11201901435UA SG11201901435UA SG11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA
- Authority
- SG
- Singapore
- Prior art keywords
- melk
- methods
- utilization
- monoclonal antibody
- antibody against
- Prior art date
Links
- 101150054634 melk gene Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 abstract 3
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 abstract 3
- DKZYXHCYPUVGAF-UHFFFAOYSA-N 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone Chemical compound CN(C)CC1CCC(CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O DKZYXHCYPUVGAF-UHFFFAOYSA-N 0.000 abstract 2
- 229940124787 MELK inhibitor Drugs 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016169085 | 2016-08-31 | ||
| PCT/JP2017/030443 WO2018043311A1 (ja) | 2016-08-31 | 2017-08-25 | Ｍｅｌｋに対するモノクローナル抗体およびその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901435UA true SG11201901435UA (en) | 2019-03-28 |
Family
ID=61301839
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901435UA SG11201901435UA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
| SG10202100683RA SG10202100683RA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100683RA SG10202100683RA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11066477B2 (zh) |
| EP (1) | EP3508576A4 (zh) |
| JP (1) | JP7094557B2 (zh) |
| KR (1) | KR102579047B1 (zh) |
| CN (1) | CN109890963B (zh) |
| AU (1) | AU2017318907B2 (zh) |
| BR (1) | BR112019003408A2 (zh) |
| CA (1) | CA3035160A1 (zh) |
| IL (1) | IL264826B1 (zh) |
| MX (1) | MX2019002269A (zh) |
| RU (1) | RU2756982C2 (zh) |
| SG (2) | SG11201901435UA (zh) |
| TW (1) | TWI780067B (zh) |
| WO (1) | WO2018043311A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220035369A (ko) * | 2019-06-07 | 2022-03-22 | 아디맵 엘엘씨 | 고 친화도 항-cd3 항체, 및 이의 생성 및 사용 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP5087059B2 (ja) | 2001-10-31 | 2012-11-28 | 杏林製薬株式会社 | ４−（２−メチル−１−イミダゾリル）−２，２−ジフェニルブタンアミドの製造方法 |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| JP2007502115A (ja) | 2003-08-14 | 2007-02-08 | エクセリクシス， インク． | ＲＡＣ経路のモディファイヤーとしてのＭＥＬＫｓおよび使用方法 |
| JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
| CN101068935B (zh) | 2004-08-10 | 2012-06-27 | 肿瘤疗法科学股份有限公司 | 与乳腺癌相关的基因和多肽 |
| EP2292796A1 (en) | 2005-02-10 | 2011-03-09 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| US20090317392A1 (en) | 2005-07-27 | 2009-12-24 | Yusuke Nakamura | Method of diagnosing small cell lung cancer |
| WO2007058977A2 (en) | 2005-11-10 | 2007-05-24 | Exelixis, Inc. | Kifs as modifiers of the rho pathway and methods of use |
| WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
| US9075066B2 (en) * | 2008-04-21 | 2015-07-07 | Korea Research Institute Of Bioscience And Biotechnology | CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer |
| TWI466680B (zh) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗 |
| TWI485245B (zh) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗 |
| EP2597955B1 (en) | 2010-07-30 | 2016-01-20 | OncoTherapy Science, Inc. | Quinoline derivatives and melk inhibitors containing the same |
| EP2574929A1 (en) | 2011-09-28 | 2013-04-03 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker in diagnosing prostate cancer (PC) |
| CN104968345B (zh) | 2012-01-19 | 2018-05-08 | 肿瘤疗法科学股份有限公司 | 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂 |
| RU2504785C1 (ru) | 2012-11-23 | 2014-01-20 | Общество с ограниченной ответственностью "Синтавр" | Способ диагностики рака молочной железы |
| ES2669450T3 (es) * | 2013-01-11 | 2018-05-25 | Novartis Ag | Regulación de MELK para el tratamiento de cáncer de mama |
| WO2016092865A1 (ja) | 2014-12-12 | 2016-06-16 | 国立大学法人京都大学 | アミロイドβの２２位及び２３位のターン構造を極めて特異的に認識する抗体 |
-
2017
- 2017-08-25 EP EP17846316.2A patent/EP3508576A4/en active Pending
- 2017-08-25 RU RU2019107355A patent/RU2756982C2/ru active
- 2017-08-25 BR BR112019003408A patent/BR112019003408A2/pt unknown
- 2017-08-25 CA CA3035160A patent/CA3035160A1/en active Pending
- 2017-08-25 JP JP2018537214A patent/JP7094557B2/ja active Active
- 2017-08-25 CN CN201780067183.0A patent/CN109890963B/zh active Active
- 2017-08-25 SG SG11201901435UA patent/SG11201901435UA/en unknown
- 2017-08-25 WO PCT/JP2017/030443 patent/WO2018043311A1/ja unknown
- 2017-08-25 US US16/328,259 patent/US11066477B2/en active Active
- 2017-08-25 MX MX2019002269A patent/MX2019002269A/es unknown
- 2017-08-25 KR KR1020197009204A patent/KR102579047B1/ko active IP Right Grant
- 2017-08-25 SG SG10202100683RA patent/SG10202100683RA/en unknown
- 2017-08-25 AU AU2017318907A patent/AU2017318907B2/en active Active
- 2017-08-25 IL IL264826A patent/IL264826B1/en unknown
- 2017-08-28 TW TW106129146A patent/TWI780067B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3508576A4 (en) | 2020-04-22 |
| KR102579047B1 (ko) | 2023-09-14 |
| CN109890963A (zh) | 2019-06-14 |
| IL264826A (zh) | 2019-04-30 |
| EP3508576A1 (en) | 2019-07-10 |
| IL264826B1 (en) | 2024-02-01 |
| CA3035160A1 (en) | 2018-03-08 |
| US20190185575A1 (en) | 2019-06-20 |
| US11066477B2 (en) | 2021-07-20 |
| WO2018043311A1 (ja) | 2018-03-08 |
| RU2019107355A (ru) | 2020-10-01 |
| JP7094557B2 (ja) | 2022-07-04 |
| SG10202100683RA (en) | 2021-03-30 |
| AU2017318907A2 (en) | 2019-03-28 |
| TW201818972A (zh) | 2018-06-01 |
| RU2756982C2 (ru) | 2021-10-07 |
| AU2017318907A1 (en) | 2019-03-21 |
| CN109890963B (zh) | 2023-10-03 |
| BR112019003408A2 (pt) | 2019-06-25 |
| RU2019107355A3 (zh) | 2020-11-02 |
| AU2017318907B2 (en) | 2023-07-06 |
| JPWO2018043311A1 (ja) | 2019-06-24 |
| MX2019002269A (es) | 2019-09-18 |
| KR20190043591A (ko) | 2019-04-26 |
| TWI780067B (zh) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3313884T2 (ro) | Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora | |
| CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| SG10201906750XA (en) | Assays for detecting the presence or amount of an anti-drug antibody | |
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| WO2014144763A3 (en) | High affinity anti-gd2 antibodies | |
| EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| CO2020004831A2 (es) | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa | |
| BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| PH12019501837A1 (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| MX2020009879A (es) | Anticuerpos anti-il-27 y sus usos. | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| EA202091569A1 (ru) | Моноклональные антитела и способы их применения | |
| ZA201804705B (en) | Monoclonal antibodies specific for the piii antigen of human adenovirus (adv), produced and secreted by cell hybridomas, useful for detection and diagnosis of adv infection | |
| EA202091577A1 (ru) | Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител | |
| MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
| EP4300101A3 (en) | Antigenic peptides and uses thereof for diagnosing and treating autism | |
| SG11201901435UA (en) | Monoclonal antibody against melk and utilization thereof | |
| BR112019006422A2 (pt) | anticorpo monoclonal contra fzd10 e utilização do mesmo | |
| SG10201903424RA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
| RU2014113841A (ru) | Способ ранней диагностики эндогенной интоксикации | |
| NZ751193A (en) | Protein biomarkers for diseases associated with the contact activation system |